Unlocking the Potential of Ribosomal Protein S10 Pseudogene 13 as a Drug Target or Biomarker

Target Name: RPS10P13

NCBI ID: G646785

RPS10P13

Other Name(s): ribosomal protein S10 pseudogene 13 | Ribosomal protein S10 pseudogene 13 | RPS10_8_685

Unlocking the Potential of Ribosomal Protein S10 Pseudogene 13 as a Drug Target or Biomarker

Introduction

Ribosomal protein S10 pseudogene 13 (RPS10P13) is a non-coding RNA molecule that plays a crucial role in the regulation of protein synthesis in eukaryotic cells. It is a key component of the ribosome, the protein synthesis machine that synthesizes proteins from amino acids. The RPS10P13 gene has been well-studied, and its functions in cell biology have been extensively investigated. However, despite its importance, RPS10P13 remains an unexplored drug target or biomarker. In this article, we will explore the potential of RPS10P13 as a drug target or biomarker and highlight its unique features that make it an attractive candidate for research.

Drug Target Potential

RPS10P13 is a promising drug target due to its various functions in cell biology. Firstly, RPS10P13 has been shown to regulate the activity of the ribosome, which is crucial for the production of proteins. It does this by interacting with the protein Lrp18, which is essential for the initiation of protein synthesis. Secondly, RPS10P13 has been shown to play a role in the regulation of gene expression. It has been shown to interact with the transcription factors, SFP1/HF1 and HF2, which are involved in the regulation of gene expression.

Biomarker Potential

RPS10P13 has also been shown to have potential as a biomarker for various diseases, including cancer. Its expression has been shown to be downregulated in various types of cancer, which suggests that it may have diagnostic and therapeutic potential in these diseases. Furthermore, the expression of RPS10P13 has been shown to be associated with the development and progression of certain diseases, such as neurodegenerative diseases. These findings make RPS10P13 an attractive candidate for biomarker research in these diseases.

Expression and Regulation

The expression of RPS10P13 is highly regulated in eukaryotic cells. It is expressed in the cytoplasm of the cell and is primarily translated into protein by the ribosome. The translation of RPS10P13 is regulated by various factors, including the amount of ribosomes available in the cell.

Structure and Function

The structure of RPS10P13 is well- conserved across various species, which indicates that it has a conserved function. It has a characteristic domain that includes a putative RNA binding structure and a conserved carboxylic acid residue, which is involved in the formation of a covalent complex with other molecules. The putative RNA binding structure is located at the N-terminus of the protein and is responsible for its stability and interaction with other molecules.

Expression and Therapeutic Potential

The expression of RPS10P13 has been shown to be involved in various cellular processes, including protein synthesis, cell growth, and apoptosis. It has been shown to play a role in the regulation of cellular processes such as cell adhesion, migration, and the development of cancer.

In conclusion, RPS10P13 is an unexplored drug target or biomarker that has various functions in cell biology. Its expression is well-regulated and it has been shown to play a role in the regulation of protein synthesis, cell growth, and apoptosis. Further research is necessary to fully understand its potential as a drug target or biomarker.

Protein Name: Ribosomal Protein S10 Pseudogene 13

The "RPS10P13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPS10P13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets